体学化验服务市场－全球产业规模、份额、趋势、机会和预测：按服务、服务频率、业务、最终用途、地区和竞争格局划分，2021-2031年

全球体学化验服务市场预计将从 2025 年的 728.8 亿美元成长到 2031 年的 1,284.8 亿美元，复合年增长率为 9.91%。

这些服务涵盖基因组学、蛋白质组学和代谢体学，为药物研发和临床应用提供关键的合约研究和诊断支援。推动成长的主要因素是慢性病发病率的上升，使得个人化医疗和精准分子分析的需求日益增长。此外，生物製药公司越来越多地将研究活动外包给专业的外部机构，以优化固定成本并获得先进技术。正如美国癌症协会所指出的，预计到2025年，美国将新增2,041,910例癌症病例，凸显了这些先进诊断能力的重要性。

儘管市场呈现成长态势，但由于资料隐私和伦理合规复杂的法规环境，该市场仍面临许多挑战。处理包含敏感基因资讯的大型资料集需要严格遵守不断发展的国际标准，这导致实验室营运成本增加，并可能带来法律责任风险。这些严格的合规义务可能会延误计划进度，并为新进业者设定高门槛，最终阻碍创新步伐，限制市场准入。

市场驱动因素

全球体学化验服务市场的主要驱动力是个人化和精准医疗的日益融合，医疗服务提供者正转向分子谱分析以客製化病患治疗方案。这种从通用处方到标靶治疗的转变需要广泛的基因组学、蛋白质组学和代谢体学检测，从而推动了专业实验室样本处理量的激增。製药开发商正大力投资生物标记研究以检验这些标靶治疗，这进一步刺激了对高复杂度外包检测的需求，以确保获得监管部门的核准和临床成功。根据个人化医疗联盟 (PMC) 2025 年 5 月发布的报告《FDA 的个人化医疗：2024 年进展的范围和意义》，FDA 预计将在 2024 年核准18 种新型个人化药物，约占新核准治疗性分子实体的 38%。这凸显了该产业对先进体学数据的依赖。

同时，对液态生物检体和非侵入性诊断工具的需求不断增长，使得在避免组织切片检查风险的前提下，能够频繁监测疾病，从而扩大了市场覆盖范围。这种转变迫使服务供应商扩展其定序基础设施和生物资讯能力，以满足癌症监测和早期检测所需的日益增多的复杂血液生物标记检测需求。 Guardant Health 在 2025 年 2 月发布的「2024 年第四季及全年业绩」报告中指出，该公司在 2024 年处理了约 206,700 例肿瘤临床检测，较去年同期成长 20%。 Exact Sciences 对 2024 年全年总收入的预测进一步印证了这一趋势的财务规模，该公司预计 2024 年全年总收入将达到 27.6 亿美元，这主要得益于对其诊断和癌症筛检服务需求的增长。

市场挑战

全球体学化验服务市场的一大障碍是复杂的法规结构，涵盖资料隐私和伦理合规。实验室处理大量的敏感基因数据，必须实施符合严格国际要求的复杂资料保护系统。这项要求需要投入大量资源，增加营运成本，并挤占研发资金，往往导致计划延期。因此，合规的财务和技术要求提高了准入门槛，阻碍了小规模、具有创新精神的公司进入市场，并促使市场被少数大型供应商垄断。

此外，资料外洩造成的严重经济损失迫使实验室将风险管理置于服务扩张之上。安全漏洞带来的成本高昂，并引发重大的责任问题。根据美国医院协会发布的《2025年环境扫描报告》，2024年医疗保健资料外洩的平均成本为977万美元。如此高的风险可能迫使各机构采用严格的数据处理通讯协定，从而阻碍合作研究，并降低市场提供及时便捷的诊断解决方案的能力。

市场趋势

人工智慧 (AI) 整合在高阶资料解读领域正成为体学领域的基础性趋势，其关注点从提供原始资料转向提供可操作的洞见。服务供应商正越来越多地将机器学习演算法融入其生物资讯学工作流程，以解读复杂的多组体学资料集，从而帮助製药客户更快、更准确地发现新的治疗标靶。这种向 AI 驱动的洞见生成的演进为技术先进的研究机构带来了巨大的商机。例如，Tempus AI 在 2025 年 2 月发布的「2024 财年第四季及全年财务业绩」中报告称，其 2024 财年总收入为 6.934 亿美元，同比增长 30.4%，这主要得益于其人工智慧能力的提升。

同时，空间体学和组织分析技术的兴起正在变革生物分析，使基因表现能够在组织结构背景下进行绘製。与分离细胞的传统定序方法不同，空间分析能够保留样本位置信息，从而为肿瘤微环境和细胞间相互作用提供关键见解，这对于肿瘤免疫学至关重要。这项进步正推动研究实验室大力投资高通量成像和空间分辨转录组学，以满足日益增长的生物製药需求。为了佐证这一趋势，10x Genomics 在其于 2025 年 1 月发布的「2024 年第四季及全年初步业绩报告」中指出，2024 年全年空间分析耗材销售额达到约 1.211 亿美元，表明这些具有上下文感知能力的解决方案正在被业界迅速采用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球体学化验服务市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依服务领域（基因体学、蛋白质体学、转录体学、代谢体学、表观遗传学）
  • 按服务频率（一次性、定期、持续性）
  • 依业务类型（医院、研究机构、诊断检查室）
  • 依最终用途（癌症、药物、生殖、其他遗传疾病）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美体学化验服务市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲体学化验服务市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区体学化验服务市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲体学化验服务市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲体学化验服务市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球体学化验服务市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies, Inc.
• Q2 Solutions LLC
• Flomics Biotech
• QIAGEN NV
• Thermo Fisher Scientific Inc.
• Illumina, Inc
• Quest Diagnostics Incorporated
• Phenoswitch Bioscience Inc.
• Spectrus Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Omics Lab Services Market is projected to expand from USD 72.88 Billion in 2025 to USD 128.48 Billion by 2031, registering a CAGR of 9.91%. These services, which include genomics, proteomics, and metabolomics, provide essential contract research and diagnostic support for pharmaceutical development and clinical applications. Growth is largely driven by the rising incidence of chronic diseases, which accelerates the need for personalized medicine and accurate molecular profiling. Additionally, biopharmaceutical firms are increasingly outsourcing research activities to external specialists to optimize fixed costs and access advanced expertise. As highlighted by the American Cancer Society, an estimated 2,041,910 new cancer cases are expected in the United States in 2025, underscoring the critical need for these sophisticated diagnostic capabilities.

Despite this growth, the market faces significant hurdles due to the intricate regulatory environment surrounding data privacy and ethical compliance. Handling vast datasets with sensitive genetic details demands rigorous adherence to shifting international standards, resulting in elevated operational expenses and potential liability risks for laboratories. These strict compliance obligations can prolong project timelines and establish high barriers for new entrants, ultimately impeding the rate of innovation and limiting market accessibility.

Market Driver

The Global Omics Lab Services Market is significantly propelled by the increasing integration of personalized and precision medicine, as healthcare providers turn to molecular profiling to customize patient treatments. This transition from generalized prescribing to targeted therapeutic approaches requires extensive genomic, proteomic, and metabolomic testing, thereby boosting the volume of samples processed by specialized labs. Pharmaceutical developers are heavily investing in biomarker research to validate these targeted therapies, fueling the demand for outsourced, high-complexity testing to ensure regulatory approval and clinical success. According to the Personalized Medicine Coalition's May 2025 report, 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024,' the FDA approved 18 new personalized medicines in 2024, representing roughly 38% of all newly approved therapeutic molecular entities, which highlights the industry's reliance on advanced omics data.

Concurrently, the rising demand for liquid biopsy and non-invasive diagnostic tools is widening the market scope by facilitating frequent disease monitoring without the risks involved in tissue biopsies. This shift compels service providers to expand their sequencing infrastructure and bioinformatic capabilities to manage the growing influx of complex blood-based biomarker tests needed for cancer surveillance and early detection. Guardant Health reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 that it processed approximately 206,700 oncology clinical tests during 2024, a 20% increase year-over-year. The financial magnitude of this trend is further demonstrated by Exact Sciences, which reported total revenue of $2.76 billion for the full year 2024 in 2025, largely attributed to the strong uptake of its diagnostic and cancer screening services.

Market Challenge

A major obstacle to the Global Omics Lab Services Market is the intricate regulatory framework governing data privacy and ethical compliance. Because laboratories handle vast amounts of sensitive genetic data, they must implement advanced data protection systems to satisfy strict international requirements. This necessity requires significant resource allocation, which increases operational costs and diverts funds away from research and development, often leading to project delays. Consequently, the financial and technical demands of compliance establish high barriers to entry, deterring smaller, innovative companies and favoring market consolidation among a few large providers.

Additionally, the severe financial implications of data breaches force laboratories to prioritize risk management over service expansion. The costs associated with security failures are prohibitive and pose significant liability concerns; the American Hospital Association's 2025 Environmental Scan report noted that the average cost of a healthcare data breach in 2024 was $9.77 million. Such high risks drive organizations to adopt restrictive data handling protocols, which can impede collaborative research efforts and slow the market's capacity to provide timely and accessible diagnostic solutions.

Market Trends

The integration of Artificial Intelligence for advanced data interpretation is emerging as a cornerstone trend in the omics sector, shifting the focus from delivering raw sequencing data to providing actionable insights. Service providers are increasingly incorporating machine learning algorithms into their bioinformatics workflows to decode complex multi-omics datasets, enabling pharmaceutical clients to discover new therapeutic targets more rapidly and accurately. This evolution toward AI-driven insight generation offers significant revenue potential for technologically advanced labs. For instance, Tempus AI reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 that it achieved a total revenue of $693.4 million for the fiscal year 2024, marking a 30.4% year-over-year increase driven largely by its enhanced AI-enabled capabilities.

In parallel, the rise of Spatial Omics and tissue profiling technologies is transforming biological analysis by allowing researchers to map gene expression within the architectural context of tissue. Unlike traditional sequencing methods that dissociate cells, spatial profiling maintains the sample's positional integrity, offering vital insights into tumor microenvironments and cellular interactions crucial for immuno-oncology. This advancement has prompted laboratories to invest significantly in high-plex imaging and spatially resolved transcriptomics to satisfy growing biopharma demand. Highlighting this trend, 10x Genomics reported in its 'Preliminary Select Fourth Quarter and Full Year 2024 Results' in January 2025 that it generated approximately $121.1 million in spatial consumables revenue for the full year 2024, demonstrating the rapid industry adoption of these context-aware solutions.

Key Market Players

• Agilent Technologies, Inc.
• Q2 Solutions LLC
• Flomics Biotech
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Illumina, Inc
• Quest Diagnostics Incorporated
• Phenoswitch Bioscience Inc.
• Spectrus Corporation

Report Scope

In this report, the Global Omics Lab Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omics Lab Services Market, By Service

• Genomics
• Proteomics
• Transcriptomics
• Metabolomics
• Epigenetics

Omics Lab Services Market, By Frequency Of Service

• One-Off
• Repeat
• Continuous

Omics Lab Services Market, By Business

• Hospitals
• Research Institutes
• Diagnostic Labs

Omics Lab Services Market, By End Use

• Cancer
• Pharmaco
• Reproductive
• Other Genetic Disease

Omics Lab Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omics Lab Services Market.

Available Customizations:

Global Omics Lab Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omics Lab Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Genomics, Proteomics, Transcriptomics, Metabolomics, Epigenetics)
  • 5.2.2. By Frequency Of Service (One-Off, Repeat, Continuous)
  • 5.2.3. By Business (Hospitals, Research Institutes, Diagnostic Labs)
  • 5.2.4. By End Use (Cancer, Pharmaco, Reproductive, Other Genetic Disease)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Omics Lab Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Frequency Of Service
  • 6.2.3. By Business
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Omics Lab Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Frequency Of Service
      • 6.3.1.2.3. By Business
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Omics Lab Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Frequency Of Service
      • 6.3.2.2.3. By Business
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Omics Lab Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Frequency Of Service
      • 6.3.3.2.3. By Business
      • 6.3.3.2.4. By End Use

7. Europe Omics Lab Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Frequency Of Service
  • 7.2.3. By Business
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Omics Lab Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Frequency Of Service
      • 7.3.1.2.3. By Business
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Omics Lab Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Frequency Of Service
      • 7.3.2.2.3. By Business
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Omics Lab Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Frequency Of Service
      • 7.3.3.2.3. By Business
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Omics Lab Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Frequency Of Service
      • 7.3.4.2.3. By Business
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Omics Lab Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Frequency Of Service
      • 7.3.5.2.3. By Business
      • 7.3.5.2.4. By End Use

8. Asia Pacific Omics Lab Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Frequency Of Service
  • 8.2.3. By Business
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Omics Lab Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Frequency Of Service
      • 8.3.1.2.3. By Business
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Omics Lab Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Frequency Of Service
      • 8.3.2.2.3. By Business
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Omics Lab Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Frequency Of Service
      • 8.3.3.2.3. By Business
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Omics Lab Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Frequency Of Service
      • 8.3.4.2.3. By Business
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Omics Lab Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Frequency Of Service
      • 8.3.5.2.3. By Business
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Omics Lab Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Frequency Of Service
  • 9.2.3. By Business
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Omics Lab Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Frequency Of Service
      • 9.3.1.2.3. By Business
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Omics Lab Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Frequency Of Service
      • 9.3.2.2.3. By Business
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Omics Lab Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Frequency Of Service
      • 9.3.3.2.3. By Business
      • 9.3.3.2.4. By End Use

10. South America Omics Lab Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Frequency Of Service
  • 10.2.3. By Business
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Omics Lab Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Frequency Of Service
      • 10.3.1.2.3. By Business
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Omics Lab Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Frequency Of Service
      • 10.3.2.2.3. By Business
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Omics Lab Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Frequency Of Service
      • 10.3.3.2.3. By Business
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Omics Lab Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Q2 Solutions LLC
• 15.3. Flomics Biotech
• 15.4. QIAGEN N.V.
• 15.5. Thermo Fisher Scientific Inc.
• 15.6. Illumina, Inc
• 15.7. Quest Diagnostics Incorporated
• 15.8. Phenoswitch Bioscience Inc.
• 15.9. Spectrus Corporation

16. Strategic Recommendations

17. About Us & Disclaimer